Moderna, Inc. (FRA:0QF)
22.62
-0.31 (-1.33%)
Aug 14, 2025, 4:44 PM CET
Moderna Revenue
Moderna had revenue of $142.00M USD in the quarter ending June 30, 2025, a decrease of -41.08%. This brings the company's revenue in the last twelve months to $3.08B, down -39.05% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.08B
Revenue Growth
-39.05%
P/S Ratio
3.41
Revenue / Employee
$530.69K
Employees
5,800
Market Cap
8.93B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Moderna News
- 5 days ago - Pfizer Covid vaccine for young children may not be renewed by FDA - The Guardian
- 7 days ago - Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - MarketWatch
- 7 days ago - Check Out What Whales Are Doing With MRNA - Benzinga
- 8 days ago - Despite RFK’s funding block, mRNA vaccines are too impressive to ignore - The Guardian
- 8 days ago - Is RFK Jr right to pull mRNA vaccine research funding? - BBC
- 8 days ago - RFK Jr cancels $500 million in mRNA research, HHS to prioritize 'safer' vaccine alternatives - Fox News
- 9 days ago - Moderna: RSV Upside Slim, Cash Burn Heavy - Seeking Alpha
- 10 days ago - Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish - Seeking Alpha